NCT06890312 Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)
| NCT ID | NCT06890312 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Coronary Angiography |
| Study Type | INTERVENTIONAL |
| Enrollment | 550 participants |
| Start Date | 2025-06-05 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 550 participants in total. It began in 2025-06-05 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.
Eligibility Criteria
Inclusion Criteria: * Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention * Subject affiliated to a social protection health insurance * Subject able to understand the objectives and risks of the research and to provide dated and signed consent * Subject who has been informed of the results of the preliminary medical examination Exclusion Criteria: * Contraindication to the use of heparin (history of heparin-induced thrombocytopenia) * Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification * Subject in an exclusion period (determined by a previous or ongoing study) * Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.) * Subject under safeguard of justice * Subject under guardianship or curatorship * Pregnancy * Breastfeeding * Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).
Contact & Investigator
Pr Patrick OHLMANN Pr Patrick OHLMANN, Professor
✉ patrick.ohlmann@chru-strasbourg.fr📞 03.69.55.09.53
Frequently Asked Questions
Who can join the NCT06890312 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Angiography. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06890312 currently recruiting?
Yes, NCT06890312 is actively recruiting participants. Contact the research team at patrick.ohlmann@chru-strasbourg.fr for enrollment information.
Where is the NCT06890312 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT06890312 clinical trial?
NCT06890312 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 550 participants.